<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543451</url>
  </required_header>
  <id_info>
    <org_study_id>TIDE-11-10</org_study_id>
    <nct_id>NCT01543451</nct_id>
  </id_info>
  <brief_title>Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea</brief_title>
  <official_title>Phase II, Double-blind, Randomized, Two-stage, Placebo-controlled Proof of Concept Study in Colorectal Cancer Patients Receiving 5-FU Based Chemotherapy to Assess the Efficacy of Elsiglutide (ZP1846)Administered s.c. in the Prevention of Chemotherapy Induced Diarrhea(CID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinn Healthcare SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study will be to obtain data on the efficacy of elsiglutide in
      preventing Chemotherapy Induced Diarrhea (CID) in patients with colorectal cancer receiving
      5-FU based chemotherapy (FOLFOX4 or FOLFIRI regimen) in comparison to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients experiencing Diarrhea</measure>
    <time_frame>Day 1 to Day 14</time_frame>
    <description>Severity of Diarrhea will be classified according to the NCI-CTCAE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the administered repeated doses of elsiglutide (ZP1846) will be evaluated</measure>
    <time_frame>Day 1 to Day 32</time_frame>
    <description>Safety will be evaluated by monitoring:
Physical examination
Vital signs
Clinical laboratory parameters (hematology, blood chemistry, urinalysis)
12-lead ECG
AEs
Immunogenicity testing in a subset of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of elsiglutide will be evaluated</measure>
    <time_frame>Day 1 to Day 5</time_frame>
    <description>The followin standard PK parameters will be evaluated:
Tmax, Cmax, AUC0-t, AUC0-24, AUC0-∞, t1/2Z, λZ, CL/F, VZ/F, the effect of multiple dosing will be evaluated (accumulation ratio). Blood sampling for PK will be performed at: pre-dose, 2h, 4, 6, 12, 24 h post-dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Elsiglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elsiglutide</intervention_name>
    <description>24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy</description>
    <arm_group_label>Elsiglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent;

          2. Male or female patient ≥ 18 years of age;

          3. Confirmed diagnosis of colorectal cancer;

          4. Chemotherapy naïve patient;

          5. Patient scheduled to receive a FOLFOX4 or FOLFIRI chemotherapy regimen according to
             the following scheme and dosage (1st cycle):

             AGENT DOSE ROUTE/DURATION DAYS Oxaliplatin or Irinotecan 85/180 mg m2 i.v. infusion/2h
             1 FolinicAcid (leucovorin) 200 mg m2 i.v. infusion/2h 1+2 5-Fluorouracil (5FU) 400 mg
             m2 i.v. bolus 1+2 5-Fluorouracil (5FU) 600 mg m2 i.v. infusion/22h 1+2

          6. A performance status of ≤ 2 according to the Eastern Cooperative Oncology Group(ECOG);

          7. Non-fertile patient or fertile patient (male or female) using reliable contraceptive
             measures

          8. Female patient of childbearing potential; need to have a negative pregnancy test at
             screening.

        Inclusion criteria 1-8 will be verified at screening.

        Inclusion criteria 8 will be re-confirmed on Day 1.

        Exclusion Criteria:

          1. Inability to understand study procedures and/or cooperate with the study Investigator;

          2. Any investigational drugs within 30 days before enrollment in the study or foreseen
             use of investigational agents during the study;

          3. Patient with any type of ostomy;

          4. Any previous radiotherapy to the abdomen or pelvis;

          5. Scheduled to receive radiotherapy to abdomen or pelvis during the study (Day 1 to Day
             14);

          6. Scheduled to receive any concomitant chemotherapeutic agent other than FOLFOX4 or
             FOLFIRI agents (Oxaliplatin, Irinotecan, Folinic acid, 5-FU) from Day 1 to Day 14;

          7. Previous use or scheduled to receive monoclonal antibodies (e.g. bevacizumab,
             cetuximab, etc) during the study (From Day 1 to Day 14);

          8. Major surgery within the previous 3 weeks;

          9. Any type of condition leading to chronic diarrhea, including but not limited to
             inflammatory bowel diseases (e.g. ulcerative colitis and Crohn's disease), chronic
             diarrhea of presumed or confirmed infectious origin and irritable bowel syndrome;

         10. Any diarrhea in the 48 hours preceding study drug administration;

         11. Use of anti-diarrheal agents within the 48 hours prior to study drug administration;

         12. Use of laxatives within 7 days prior to study drug administration;

         13. Use of antibiotics within 7 days prior to study drug administration;

         14. History of chronic (≥ 30 consecutive days) use of laxatives;

         15. Active and ongoing systemic infection;

         16. Lactating woman;

         17. History of hypersensitivity or allergies to drugs or compounds potentially related to
             this investigational drug class;

         18. Previous exposure to GLP-2 or other compounds in this investigational drug class;

         19. Abnormal laboratory values, including

               -  Aspartate aminotransferase (AST) ≥ 5 x upper limit of normal

               -  Alanine aminotransferase (ALT) ≥ 5 x upper limit of normal

               -  Bilirubin &gt; 2 mg/dL (34 μmol/L)

               -  Creatinine &gt; 2 mg/dL (177 μmol/L)

               -  Albumine &lt; 2 g/dL (20 g/L)

               -  Neutrophils&lt; 1.5 x109/L

               -  Platelet count &lt; 100 x109/L;

         20. Concomitant bleeding disorders;

         21. Other serious concomitant illness, which could interfere with the study;

         22. Patient who participated in a previous study with elsiglutide (ZP1846).

        Exclusion criteria 1-9 and 12-22 will be verified at screening. Exclusion criteria 10 and
        11 will be checked on Day 1 only. Exclusion criteria 12, 13 and 15 will be re-checked on
        Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Chemotherapy, Complex Oncology Center</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chemotherapy Department, Complex Oncology Center</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Chemotherapy Specialized Hospital for Active Treatment of Oncological Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Chemotherapy Specialized Hospital for Active Treatment of Oncological Diseases</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Clinic, Multiprofile Hospital for Active Treatment &quot;Sveta Marina&quot;</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, Department of Diagnostic Radiology and Oncotherapy</name>
      <address>
        <city>Budapest</city>
        <zip>H-1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenezy Hospital, Department of Clinical Pharmacology, Infectology and Allergology</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar County Teaching Hospital, Center of Oncologic Radiology Hungary</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szeged Medical University Department of Oncology and Oncotherapy</name>
      <address>
        <city>Szeged</city>
        <zip>H-6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Ion Chiricuta Institute of Oncology, Medical Oncology Department</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj County</state>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Euroclinic Oncology Center SRL - Medical Oncology Department</name>
      <address>
        <city>Iasi</city>
        <state>Iasi county</state>
        <zip>700106</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Constantin Opris Clinical Country Emergency Hospital Baia Mare, Department of Oncology</name>
      <address>
        <city>Baia Mare</city>
        <state>Maramures County</state>
        <zip>430031</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sf. Ioan cel Nou Emergency Clincal County Hospital</name>
      <address>
        <city>Suceava</city>
        <state>Suceava county</state>
        <zip>720237</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundeni Clinical Institute - Medical Oncology Department</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City #9 Hospital</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>St. Petersburg</state>
        <zip>197110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Oncology Center</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>St. Petersburg</state>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncology Center - Chemotherapy Department</name>
      <address>
        <city>Ulyanovsk</city>
        <state>Ulyanovsk region</state>
        <zip>432063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Oncology Center</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kursk Regional Clinical Oncology Center</name>
      <address>
        <city>Kursk</city>
        <zip>305035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pyatigorsk Oncology Center</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Oncology Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Romania</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <disposition_first_submitted>February 27, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>February 27, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 26, 2014</disposition_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

